Menu

Merck

Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Naïve and Difficult-to-Cure Patients

, , ,

Final Results from the C-WORTHy Study (Parts A and B) Presented at The Liver Meeting® and Published in The Lancet First Wave of Phase 3 Development Program for Grazoprevir/Elbasvir is Fully Enrolled; Merck Plans to Submit New Drug Application in 2015 BOSTON, November 11, 2014–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and […]

Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting®

, ,

Merck Plans to Initiate Phase 2 C-CREST Program to Evaluate Merck’s Triple Combination of Grazoprevir/Elbasvir with MK-3682 (formerly IDX21437), a Novel Nucleotide Inhibitor, in Q1 2015 BOSTON, November 9, 2014–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential […]

New Studies Investigating the Use of KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time

, , ,

By Year End, Data on KEYTRUDA in Seven Tumor Types Will Have Been Presented WHITEHOUSE STATION, N.J., November 6, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA® (pembrolizumab) – the […]

Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

, ,

October 27, 2014 – WHITEHOUSE STATION, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with Epidermal Growth Factor Receptor (EGFR) mutation-negative, and Anaplastic Lymphoma […]

US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine

,

Phase III clinical study data presented at IDWeek in Philadelphia October 20, 2014 – WHITEHOUSE STATION, N.J. & SWIFTWATER, Pa.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT:SAN and NYSE:SNY), announced today that the Biologics License Application (BLA) filed for the companies’ investigational […]

Merck Advances Development Program for Investigational Alzheimer’s Disease Therapy, MK-8931

, , , ,

Data Monitoring Committee recommends continuation of Phase II/III EPOCH study in mild to moderate disease patients Merck also plans to initiate dosing in Phase III study of prodromal disease patients WHITEHOUSE STATION, N.J. December 10, 2013 — (BUSINESS WIRE) –Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the […]

Forest to Acquire U.S. Marketing Rights to Saphris® (asenapine) from Merck

, , , ,

Forest acquires exclusive rights to Saphris® in the United States for the treatment of schizophrenia and acute bipolar mania in adults for $240 million plus sales-based milestones and on-going supply payments Saphris is complementary to Forest’s existing CNS franchise and commercial infrastructure Agreement is expected to be immediately accretive to Forest NEW YORK —  December […]

FDA Approves Merck’s NOXAFIL® (posaconazole) Delayed-Release Tablets

, , ,

WHITEHOUSE STATION, N.J.  November 26, 2013 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets. NOXAFIL delayed-release tablets are a new formulation with a loading dose of 300 mg (three 100 mg delayed-release tablets) twice […]

«‹ 2 3 4 5